Literature DB >> 17437505

Predictors of medication adherence in inflammatory bowel disease.

Jason P Ediger1, John R Walker, Lesley Graff, Lisa Lix, Ian Clara, Patricia Rawsthorne, Linda Rogala, Norine Miller, Cory McPhail, Kathleen Deering, Charles N Bernstein.   

Abstract

BACKGROUND AND AIMS: This study reports cross-sectional medication adherence data from year 1 of the Manitoba Inflammatory Bowel Disease (IBD) Cohort Study, a longitudinal, population-based study of multiple determinants of health outcomes in IBD in those diagnosed within 7 yr.
METHODS: A total of 326 participants completed a validated multi-item self-report measure of adherence, which assesses a range of adherence behaviors. Demographic, clinical, and psycho-social characteristics were also assessed by survey. Adherence was initially considered as a continuous variable and then categorized as high or low adherence for logistic regression analysis to determine predictors of adherence behavior.
RESULTS: Using the cutoff score of 20/25 on the Medication Adherence Report Scale, high adherence was reported by 73% of men and 63% of women. For men, predictors of low adherence included diagnosis (UC: OR 4.42, 95% CI 1.66-11.75) and employment status (employed: OR 11.27, 95% CI 2.05-62.08). For women, predictors of low adherence included younger age (under 30 versus over 50 OR 3.64, 95% CI 1.41-9.43; under 30 vs. 40-49 yr: OR 2.62, 95% CI 1.07-6.42). High scores on the Obstacles to Medication Use Scale strongly related to low adherence for both men (OR 4.05, 95% CI 1.40-11.70) and women (OR 3.89, 95% CI 1.90-7.99). 5-ASA use (oral or rectal) was not related to adherence. For women, immunosuppressant use versus no use was associated with high adherence (OR 4.49, 95% CI 1.58-12.76). Low trait agreeableness was associated with low adherence (OR 2.03, 95% CI 1.12-3.66).
CONCLUSIONS: Approximately one-third of IBD patients were low adherers. Predictors of adherence differed markedly between genders, although obstacles such as medication cost were relevant for both men and women.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17437505     DOI: 10.1111/j.1572-0241.2007.01212.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  76 in total

1.  Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment.

Authors:  Paul Hodgkins; Paul Swinburn; Dory Solomon; Linnette Yen; Sarah Dewilde; Andrew Lloyd
Journal:  Patient       Date:  2012       Impact factor: 3.883

Review 2.  Systematic review: The role of race and socioeconomic factors on IBD healthcare delivery and effectiveness.

Authors:  Justin L Sewell; Fernando S Velayos
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

3.  IBD: Stress causes flares of IBD--how much evidence is enough?

Authors:  Jane M Andrews; Gerald Holtmann
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-01       Impact factor: 46.802

4.  Satisfaction with patient-doctor relationships in inflammatory bowel diseases: examining patient-initiated change of specialist.

Authors:  Daniel R van Langenberg; Jane M Andrews
Journal:  World J Gastroenterol       Date:  2012-05-14       Impact factor: 5.742

5.  Optimizing management of Crohn's disease within a project management framework: results of a pilot study.

Authors:  Laurie Keefer; Bethany Doerfler; Caroline Artz
Journal:  Inflamm Bowel Dis       Date:  2011-02-23       Impact factor: 5.325

Review 6.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Authors:  Yongjun Wang; Claire E Parker; Tania Bhanji; Brian G Feagan; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2016-04-21

7.  Effect of TELEmedicine for Inflammatory Bowel Disease on Patient Activation and Self-Efficacy.

Authors:  Zaid Bilgrami; Ameer Abutaleb; Kenechukwu Chudy-Onwugaje; Patricia Langenberg; Miguel Regueiro; David A Schwartz; J Kathleen Tracy; Leyla Ghazi; Seema A Patil; Sandra M Quezada; Katharine M Russman; Charlene C Quinn; Guruprasad Jambaulikar; Dawn B Beaulieu; Sara Horst; Raymond K Cross
Journal:  Dig Dis Sci       Date:  2019-01-02       Impact factor: 3.199

8.  Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease.

Authors:  Geoffrey C Nguyen; Thomas A LaVeist; Mary L Harris; Lisa W Datta; Theodore M Bayless; Steven R Brant
Journal:  Inflamm Bowel Dis       Date:  2009-08       Impact factor: 5.325

9.  Predictors of medication adherence in pediatric inflammatory bowel disease patients at the Stollery Children's Hospital.

Authors:  L Kitney; J M Turner; D Spady; B Malik; W El-Matary; R Persad; H Q Huynh
Journal:  Can J Gastroenterol       Date:  2009-12       Impact factor: 3.522

10.  Objective versus subjective assessment of oral medication adherence in pediatric inflammatory bowel disease.

Authors:  Kevin A Hommel; Christine M Davis; Robert N Baldassano
Journal:  Inflamm Bowel Dis       Date:  2009-04       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.